Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Due to system maintenance, login and edit functionaility is currently unavailable

Edward L. Giovannucci, D.Sc., M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Edward Giovannucci and Philip Kantoff.
Edward Giovannucci
Connection Strength
1.888
Philip Kantoff
  1. CAG repeat within the androgen receptor gene and incidence of surgery for benign prostatic hyperplasia in U.S. physicians. Prostate. 1999 May; 39(2):130-4.
    View in: PubMed
    Score: 0.203
  2. Intratumoral Sterol-27-Hydroxylase (CYP27A1) Expression in Relation to Cholesterol Synthesis and Vitamin D Signaling and Its Association with Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2019 06; 28(6):1052-1058.
    View in: PubMed
    Score: 0.201
  3. The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. Urology. 1999 Jan; 53(1):121-5.
    View in: PubMed
    Score: 0.199
  4. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A. 1997 Apr 01; 94(7):3320-3.
    View in: PubMed
    Score: 0.176
  5. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol. 2011 Jun 10; 29(17):2378-85.
    View in: PubMed
    Score: 0.117
  6. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev. 2005 May; 14(5):1262-9.
    View in: PubMed
    Score: 0.077
  7. ATAAA repeat upstream of glutathione S-transferase P1 and prostate cancer risk. Urology. 2002 Jan; 59(1):159-64.
    View in: PubMed
    Score: 0.061
  8. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst. 2000 Dec 20; 92(24):2009-17.
    View in: PubMed
    Score: 0.057
  9. No association between the I105V polymorphism of the glutathione S-transferase P1 gene (GSTP1) and prostate cancer risk: a prospective study. Cancer Epidemiol Biomarkers Prev. 2000 Nov; 9(11):1267-8.
    View in: PubMed
    Score: 0.056
  10. Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):1086-1093.
    View in: PubMed
    Score: 0.053
  11. Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer. Int J Cancer. 2020 05 15; 146(10):2694-2702.
    View in: PubMed
    Score: 0.052
  12. The androgen receptor CAG repeat polymorphism and its relationship to prostate cancer. Biochim Biophys Acta. 1998 Nov 26; 1378(3):C1-5.
    View in: PubMed
    Score: 0.049
  13. The androgen receptor gene GGN microsatellite and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 1998 May; 7(5):379-84.
    View in: PubMed
    Score: 0.047
  14. The epidemic of prostate cancer and the medical literature: a causal association? Prostate Cancer Prostatic Dis. 1998 Mar; 1(3):148-153.
    View in: PubMed
    Score: 0.047
  15. Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer. Cancer. 2017 Nov 01; 123(21):4130-4138.
    View in: PubMed
    Score: 0.045
  16. A polymorphism of the 5 alpha-reductase gene and its association with prostate cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 1997 Mar; 6(3):189-92.
    View in: PubMed
    Score: 0.044
  17. The ABC model of prostate cancer: A conceptual framework for the design and interpretation of prognostic studies. Cancer. 2017 05 01; 123(9):1490-1496.
    View in: PubMed
    Score: 0.044
  18. The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study. Cancer Metab. 2016; 4:22.
    View in: PubMed
    Score: 0.043
  19. Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2014 Oct; 23(10):2027-31.
    View in: PubMed
    Score: 0.036
  20. SPINK1 protein expression and prostate cancer progression. Clin Cancer Res. 2014 Sep 15; 20(18):4904-11.
    View in: PubMed
    Score: 0.036
  21. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. J Natl Cancer Inst. 2013 Dec 18; 105(24):1881-90.
    View in: PubMed
    Score: 0.035
  22. A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer. Clin Cancer Res. 2013 Mar 15; 19(6):1612-9.
    View in: PubMed
    Score: 0.033
  23. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012 Sep; 21(9):1497-509.
    View in: PubMed
    Score: 0.032
  24. Genome-wide association study of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev. 2010 Nov; 19(11):2869-76.
    View in: PubMed
    Score: 0.028
  25. Immunohistochemical expression of BRCA1 and lethal prostate cancer. Cancer Res. 2010 Apr 15; 70(8):3136-9.
    View in: PubMed
    Score: 0.027
  26. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res. 2005 Mar 15; 65(6):2498-504.
    View in: PubMed
    Score: 0.019
  27. Association between the Met326Ile polymorphism of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase and prostate cancer risk: a prospective study. Cancer Epidemiol Biomarkers Prev. 2003 Feb; 12(2):172-3.
    View in: PubMed
    Score: 0.016
  28. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2001 Jul; 10(7):743-8.
    View in: PubMed
    Score: 0.015
  29. PTEN polymorphism (IVS4) is not associated with risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2001 Apr; 10(4):411-2.
    View in: PubMed
    Score: 0.015
  30. The V89L polymorphism in the 5alpha-reductase type 2 gene and risk of prostate cancer. Cancer Res. 1999 Dec 01; 59(23):5878-81.
    View in: PubMed
    Score: 0.013
  31. Debrisoquine hydroxylase (CYP2D6) and prostate cancer. Cancer Epidemiol Biomarkers Prev. 1998 Dec; 7(12):1075-8.
    View in: PubMed
    Score: 0.012
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.